![]() ![]() Each participant was selected for their promise and commitment to innovation, she said. Busby, director of the BioVenture eLab, highlighted the teams’ journeys from the start of the mentorship program to the pitch event. Samuel Hall, managing partner at Scion Life Sciences. '12), managing director of 6 Dimensions Capital and Dr. Misti Ushio, managing partner at Digitalis Ventures Dr. Sonia Gulati, principal at Global BioAccess Fund Dr. Uya Chuluunbaatar, partner at Avoro Ventures Dr. Artavazd Arumov, vice president of Qiming Ventures (U.S.) Dr. The judging panel featured a wide range of disciplines and expertise, and included Dr. What was at stake was $100,000 in prize money, which can be used to help build the company, with the goal of ushering in the next generation of life science innovation and patient care. Hani Najafi, an assistant professor of cell and developmental biology. This year’s Business Plan Challenge also included an entry from Weill Cornell Medicine–Qatar represented by Dr. The presentations exemplified the diverse innovations fostered by Weill Cornell Medicine, from utilizing MicroRNA technology to treat obesity and high cholesterol, to harnessing novel small molecules to treat metabolic diseases and cancer. “It has rapidly become one of Enterprise Innovation’s signature programs, helping to build Weill Cornell Medicine’s culture of innovation and entrepreneurship, as well as the broader New York City ecosystem.” ![]() “The annual Business Plan Challenge has proven to be one of our most popular and impactful events”, said Larry Schlossman, managing director of BioPharma Alliances and Research Collaborations, which oversees the BioVenture eLab. The challenge marks the culmination of 10 weeks of research, collaboration and business development at Weill Cornell Medicine, during which entrepreneurial scientists immerse themselves in an intensive mentoring program to build and refine a complete business plan that will ultimately be presented before a panel of biomedical venture investors. BioVenture eLab helps Weill Cornell Medicine scientists and clinicians curate, launch, capitalize and recruit management for their companies, known in the industry as NewCos, in order to translate their inventions into new therapeutics, diagnostics and medical devices that will be available in the clinic. Zhou’s presentation was one of six pitches at the 2023 Biomedical Business Plan Challenge Final Pitch Day competition, an annual event organized by Weill Cornell Medicine’s BioVenture eLab, part of Enterprise Innovation. Xiaofeng Steve Huang, are forming a company, tentatively named Cell Programming Technologies, which they pitched to a panel of judges––each with deep domain expertise as evaluators of new technology––as the future in diabetes treatment.ĭr. This cell therapy approach has the potential to eliminate constant glucose monitoring and insulin injection and, by providing precise dosing, may reduce the risk of debilitating long-term complications brought on by diabetes. In pre-clinical studies, transplantation of these human organoids stabilized blood sugar for as long as the grafts were in place. These organoids can detect blood glucose fluctuations and secrete just the right amount of insulin to counteract the rise of blood sugar, similar to pancreatic islets. ![]() Zhou and his research team at the Hartman Institute for Therapeutic Organ Regeneration have developed an innovative cell therapy that creates insulin-producing pancreatic islet-like cell clusters, or organoids, that derive from an individual’s own stomach cells. Harnessing the power of regenerative medicine, Dr. Bolus insulin injections often lead to imprecise dosing and over time, serious complications such as neuropathy and retinopathy develop, greatly reducing the quality of life. These are very difficult to manage for adults, let alone millions of children with type 1 diabetes. Millions of diabetic patients rely on daily finger pricks to monitor blood glucose and insulin injections to control hyperglycemia. It leads to roughly 4 million deaths annually due to complications and racks up nearly a trillion in health care spending. More than 400 million people globally live with diabetes. ![]() Joe Zhou, an associate professor in regenerative medicine in medicine at Weill Cornell Medicine, made the case for the necessity of developing new approaches to treat diabetes, a disease he called “a true epidemic of the modern world.” Standing on the stage at Uris Auditorium on June 1, Dr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |